Patent ID: 11939604
Assignee: CARIBOU BIOSCIENCES, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of modifying a target nucleic acid comprising:
contacting the target nucleic acid with a Type I CRISPR composition comprising:
a Type I CASCADE protein complex comprising a Cse1 subunit protein, having an N-terminus and a C-terminus,
a Cas3 K320N mutant protein, and
a CRISPR-derived RNA (crRNA) molecule comprising a spacer sequence complementary to the target nucleic acid;
wherein the Cas3 mutant protein comprises an Escherichia coli Cas3 mutant protein and the Cas3 mutant protein is fused to the N-terminus of the Cse1 subunit protein by a linker polypeptide.